Home » Stocks » BIOC

Biocept, Inc. (BIOC)

Stock Price: $5.12 USD 0.26 (5.35%)
Updated December 3, 4:00 PM EST - Market closed
After-hours: $5.14 +0.02 (0.39%) Dec 3, 7:58 PM

Stock Price Chart

Key Info

Market Cap 68.59M
Revenue (ttm) 10.73M
Net Income (ttm) -25.45M
Shares Out 11.32M
EPS (ttm) -2.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 3
Last Price $5.12
Previous Close $4.86
Change ($) 0.26
Change (%) 5.35%
Day's Open 4.84
Day's Range 4.72 - 5.15
Day's Volume 569,569
52-Week Range 2.38 - 11.40

More Stats

Market Cap 68.59M
Enterprise Value 54.44M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 11.32M
Float n/a
EPS (basic) -3.23
EPS (diluted) -2.37
FCF / Share -2.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 369,103
Short Ratio 0.76
Short % of Float n/a
Beta 0.92
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.39
PB Ratio 2.79
Revenue 10.73M
Operating Income -23.09M
Net Income -25.45M
Free Cash Flow -24.66M
Net Cash 14.15M
Net Cash / Share 1.06
Gross Margin -50.76%
Operating Margin -215.08%
Profit Margin -237.10%
FCF Margin -229.72%
ROA -60.98%
ROE -174.97%
ROIC -402.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$20.00*
(290.63% upside)
Low
20.0
Current: $5.12
High
20.0
Target: 20.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue5.533.255.073.220.610.130.130.11-
Revenue Growth70.09%-35.87%57.26%428.46%357.15%-0.62%22.83%10288.69%-
Gross Profit-5.45-6.80-4.28-3.70-3.99-2.04-2.20-1.09-0.02
Operating Income-23.06-24.26-21.17-18.03-16.41-13.87-7.94-10.50-12.27
Net Income-25.14-24.57-21.61-18.40-16.95-15.87-9.23-12.26-13.63
Shares Outstanding2.070.280.090.030.02----
Earnings Per Share-12.20-90.10-235.80-576.30-921.09-3,573.39-45,725.03-68,794.57-107,840.86
Operating Cash Flow-23.05-22.36-19.65-15.70-15.15-14.58-6.20-8.61-10.98
Capital Expenditures-0.74-0.15-1.40-0.45-0.17-0.39--0.01-0.30
Free Cash Flow-23.78-22.50-21.05-16.15-15.32-14.97-6.20-8.62-11.28
Cash & Equivalents9.303.422.154.618.825.360.070.190.44
Total Debt2.541.632.794.174.674.897.4022.6314.01
Net Cash / Debt6.761.80-0.640.434.150.47-7.33-22.44-13.58
Assets17.738.757.387.5810.596.571.331.472.06
Liabilities6.535.716.086.926.896.7913.7928.8517.44
Book Value11.203.041.300.663.69-0.22-12.46-27.38-15.38
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biocept, Inc.
Country United States
Employees 88
CEO Michael Nall

Stock Information

Ticker Symbol BIOC
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: BIOC
IPO Date February 5, 2014

Description

Biocept, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. The company's Target-Selector molecular technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, as well as is applicable to nucleic acid from ctDNA. In addition, it offers laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians to determine the treatment plan for their patients, as well as to pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, laboratories, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.